Skip to Content
Merck
CN
  • D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia.

D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia.

iScience (2022-10-25)
Ermanno Florio, Marcello Serra, Robert G Lewis, Enikö Kramár, Michael Freidberg, Marcello Wood, Micaela Morelli, Emiliana Borrelli
ABSTRACT

Degeneration of dopaminergic neurons leads to Parkinson's disease (PD), characterized by reduced levels of striatal dopamine (DA) and impaired voluntary movements. DA replacement is achieved by levodopa treatment which in long-term causes involuntary movements or dyskinesia. Dyskinesia is linked to the pulsatile activation of D1 receptors of the striatal medium spiny neurons (MSNs) forming the direct output pathway (dMSNs). The contribution of DA stimulation of D2R in MSNs of the indirect pathway (iMSNs) is less clear. Using the 6-hydroxydopamine model of PD, here we show that loss of DA-mediated inhibition of these neurons intensifies levodopa-induced dyskinesia (LID) leading to reprogramming of striatal gene expression. We propose that the motor impairments characteristic of PD and of its therapy are critically dependent on D2R-mediated iMSNs activity. D2R signaling not only filters inputs to the striatum but also indirectly regulates dMSNs mediated responses.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Choline Acetyltransferase Antibody, Chemicon®, from goat
Sigma-Aldrich
Goat Anti-Rabbit IgG Antibody, F(ab′)2, HRP conjugate, Chemicon®, from goat